Trinity Delta Lighthouse: HUTCHMED
Trinity Delta view: This $100m equity raise provides a useful reminder of the progress HUTCHMED is making across multiple fronts and ensures that sufficient funding is in place to maintain momentum. 2021 will see tangible signs of the value of its R&D organisation as the Oncology/Immunology commercial operations are expected to generate $110m-$130m in revenues. We see scope for significant upside potential from expected increased visibility for the three lead assets, both clinically and commercially, over the next six to 18 months, as well as the progress of earlier stage programmes, particularly HMPL-689 and HMPL-523. Our valuation, updated for the raise, is $6.37bn ($42.80 per ADS) or £4.90bn (658p/share) vs $6.27bn ($43.10/ADS) or £4.83bn (663p/share) previously. This is based on conservative assumptions, with the anticipation of further value uplifts as progress is achieved.Hutchison China MediTech is engaged in researching, developing, manufacturing and selling pharmaceuticals and healthcare products. Co. has research and development facilities and manufacturing plants in Shanghai and Guangzhou in the People's Republic of China and sells its products mainly in the PRC and Hong Kong. Co. operates two operating segments. The Innovation Platform focuses on discovering and developing therapeutics in oncology and autoimmune diseases, and the provision of research and development services. The Commercial Platform involves the manufacture, marketing and distribution of prescription and over the counter pharmaceuticals as well as consumer health products.
We are experienced healthcare and life sciences analysts providing the highest quality service to companies in these sectors and to investors. We have expertise in the fields of the biotech, medtech , specialty pharma and consumer health sectors.
The old-fashioned values of the City enabled London to become a global financial centre, and we pride ourselves for our integrity and professionalism, where our word is our bond. This applies to our research, and all interactions with companies, the buyside and other partners.
We also firmly believe that by putting our clients first, we create long term value for all stakeholders.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.